Coya Therapeutics, Inc. (NASDAQ: COYA) shares traded lower Friday. The company, a clinical-stage biotechnology concern developing biologics intended to enhance regulatory T cell (Treg) function announces that data from the IIT, a double-blind, placebo-controlled, phase 2 clinical trial of interleukin-2 (IL-2) in patients with mild to moderate Alzheimer’s Disease, conducted at Houston Methodist Research Institute and supported by the Gates Foundation and the Alzheimer’s Association will be presented at the 17th edition of the Clinical Trials on Alzheimer’s Disease Conference (CTAD24), to be held in Madrid, Spain from October 29 – November 1.
Dr. Alireza Faridar, Professor of Neurology at Houston Methodist and Principal Investigator, commented: “I am eagerly looking forward to the opportunity to present a comprehensive dataset at Alzheimer’s Disease focused conference, the CTAD24. I thank the patients, their families as well as the Gates Foundation, Alzheimer’s Association, and Coya Therapeutics for their support in this study.”
Alzheimer’s disease is the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer’s disease accounts for up to 80% of dementia cases, affecting an estimated 5.7 million Americans.
COYA dipped two cents to $6.77.
